The estimated Net Worth of Shefali Agarwal is at least $4.15 Million dollars as of 9 August 2022. Shefali Agarwal owns over 500,000 units of Epizyme Inc stock worth over $968,313 and over the last 6 years he sold EPZM stock worth over $292,524. In addition, he makes $2,887,210 as Chief Medical Officer at Epizyme Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Shefali Agarwal EPZM stock SEC Form 4 insiders trading
Shefali has made over 14 trades of the Epizyme Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 500,000 units of EPZM stock worth $695,000 on 9 August 2022.
The largest trade he's ever made was exercising 500,000 units of Epizyme Inc stock on 9 August 2022 worth over $695,000. On average, Shefali trades about 15,445 units every 34 days since 2018. As of 9 August 2022 he still owns at least 658,716 units of Epizyme Inc stock.
You can see the complete history of Shefali Agarwal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Shefali Agarwal biography
Dr. Shefali Agarwal serves as Chief Medical Officer of the Company. Prior to joining us, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as Chief Medical Officer at SQZ Biotech, a biotechnology company developing cell therapies for patients with a wide range of diseases, from uly 2017 to May 2018 and as a non-executive advisor from May 2018 to July 2018, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis, Inc. a biotechnology company developing therapeutics for the treatment of cancer, from July 2016 to July 2017 and TESARO, Inc., an oncology-focused biopharmaceutical company, from July 213 to July 2017. At Curis, Inc., Dr. Agarwal oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At TESARO, Inc., Dr. Agarwal led the New Drug Application and European Medicines Agency submissions for ZEJULA® (niraparib) in ovarian cancer. Dr. Agarwal also held positions of increasing responsibility at Covidien plc, a medical devices and health care products company, fro April2010 to December 2011, AVEO Pharmaceuticals, Inc., a biopharmaceutical company advancing targeted oncology medicines, from December 2011 to July 2013 and Pfizer Inc., a pharmaceutical company with a wide range of treatments, from June 2005 to April 2010. Dr. Agarwal received her MBBS medical degree from Karnataka University’s Mahadevappa Rampure Medical School in India, Master’s Degree in Public Health from Johns Hopkins University, where she led clinical research in the Department of Anesthesiology and Critical Care Medicine, and a Master of Science degree in Business from the University of Baltimore’s Merrick School of Business.
What is the salary of Shefali Agarwal?
As the Chief Medical Officer of Epizyme Inc, the total compensation of Shefali Agarwal at Epizyme Inc is $2,887,210. There are 1 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.
How old is Shefali Agarwal?
Shefali Agarwal is 46, he's been the Chief Medical Officer of Epizyme Inc since 2018. There are 18 older and 1 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
What's Shefali Agarwal's mailing address?
Shefali's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.
Insiders trading at Epizyme Inc
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
What does Epizyme Inc do?
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
What does Epizyme Inc's logo look like?
Complete history of Shefali Agarwal stock trades at Epizyme Inc, Fate Therapeutics Inc, and Gritstone Bio Inc
Epizyme Inc executives and stock owners
Epizyme Inc executives and other stock owners filed with the SEC include:
-
Robert Bazemore,
President, Chief Executive Officer, Director -
Shefali Agarwal,
Chief Medical Officer -
Paolo Tombesi,
Chief Financial Officer -
Matthew Ros,
Chief Strategy and Business Officer -
Dr. Shefali Agarwal M.D., MPH,
Exec. VP and Chief Medical & Devel. Officer -
Matthew E. Ros,
Advisor -
Dr. Jeffery L. Kutok M.D., Ph.D.,
Chief Scientific Officer -
Pablo Legorreta,
Director -
Grant Bogle,
Independent Director -
Victoria Richon,
Independent Director -
David Mott,
Independent Chairman of the Board -
Carl Goldfischer,
Independent Director -
Kenneth Bate,
Independent Director -
Andrew Allen,
Independent Director -
Kevin Conroy,
Independent Director -
Michael Giordano,
Director -
Grant C. Bogle,
Pres, CEO, Principal Financial Officer & Director -
Alicia Davis,
IR Contact Officer -
Jeffery Kutok,
Chief Scientific Officer -
Erin Boyer,
Chief People & Culture Officer -
Craig West CFA,
VP of Investor Relations -
John F. Weidenbruch,
Sr. VP, Gen. Counsel & Sec. -
Jason Fredette,
VP of Investor Relations -
Dr. Jeffery L. Kutok,
Chief Scientific Officer -
Joseph Beaulieu,
Controller, Treasurer & Principal Accounting Officer -
Dr. Yi Zhang,
Scientific Co-Founder & Member of The Scientific Advisory Board -
Dr. H. Robert Horvitz,
Co-Founder & Chairman of the Scientific Advisory Board -
Robert A Copeland,
EVP and CSO -
Richard F Pops,
Director -
Susan E Graf,
Chief Business Officer -
Peter Tai Ching Ho,
Chief Development Officer -
Pablo G.Rp Management, Llcr...,
-
Beth C Seidenberg,
Director -
Joseph Beaulieu,
See Remarks -
Suzanne Fleming,
SVP -
M James Barrett,
10% owner -
Ryan D Drant,
10% owner -
Xiii Associates, Llckleiner...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Perkins Caufield & Byers Xi...,
-
Patrick J Kerins,
10% owner -
City Capital Llc Bay City C...,
-
Scott D Sandell,
10% owner -
European Investment Co Llcc...,
-
Robert J Gould,
President and CEO -
Venture Fund I L.P.Astellas...,
-
Stephen Garbacz,
Principal Accounting Officer -
Ventures Llcamgen Inc Amgen,
-
City Capital Llc Bay City C...,
-
Lukegadicke Ansbert Evnin,
-
Harry R Weller,
10% owner -
Ravi Viswanathan,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Peter J Barris,
10% owner -
Forest Baskett,
10% owner -
Enterprise Associates 13 Lp...,
10% owner -
Kazumi Shiosaki,
Director -
Jason P Rhodes,
President, CFO and Treasurer -
Enterprise Associates 13 Lp...,
-
City Capital Llc Bay City C...,
-
Eric Hedrick,
Chief Medical Officer -
Partners 13, Limited Partne...,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Victoria Vakiener,
Chief Commercial Officer -
Jerald Korn,
Chief Operating Officer -
Carol Stuckley,
Director -
Roy A Beveridge,,
Director -
Pablo G.Rp Management, Llcr...,